Lobe Sciences Stock Forecast, Price & News

0.00 (-4.01 %)
(As of 05/10/2021 03:52 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume428,607 shs
Average Volume1.03 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GTSIF News and Ratings via Email

Sign-up to receive the latest news and ratings for Lobe Sciences and its competitors with MarketBeat's FREE daily newsletter.

Lobe Sciences logo

About Lobe Sciences

Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1994th out of 2,045 stocks

Drug Manufacturers—Specialty & Generic Industry

77th out of 84 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Lobe Sciences (OTCMKTS:GTSIF) Frequently Asked Questions

What stocks does MarketBeat like better than Lobe Sciences?

Wall Street analysts have given Lobe Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lobe Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lobe Sciences?

Lobe Sciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 39,800 shares, an increase of 255.4% from the March 31st total of 11,200 shares. Based on an average daily volume of 471,600 shares, the days-to-cover ratio is presently 0.1 days.
View Lobe Sciences' Short Interest

Who are Lobe Sciences' key executives?

Lobe Sciences' management team includes the following people:
  • Mr. Jonathan R. Gilbert, Exec. Chairman (Age 50)
  • Mr. Philip J. Young, CEO, Corp. Sec. & Director (Age 64)
  • Mr. Brian Zasitko, Chief Financial Officer
  • Mr. Daniel S. McAtee, Chief Operating Officer (Age 55)
  • Mr. Maghsoud Dariani, Chief Science Officer (Age 68)

Who are some of Lobe Sciences' key competitors?

What is Lobe Sciences' stock symbol?

Lobe Sciences trades on the OTCMKTS under the ticker symbol "GTSIF."

How do I buy shares of Lobe Sciences?

Shares of GTSIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lobe Sciences' stock price today?

One share of GTSIF stock can currently be purchased for approximately $0.09.

What is Lobe Sciences' official website?

The official website for Lobe Sciences is www.greenstarbiosciences.com.

How can I contact Lobe Sciences?

The company can be reached via phone at 604-834-9499.

This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.